Jazz Pharmaceuticals PLC (JAZZ)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	294,908	-106,935	-269,230	-330,792	-382,741	-89,793	-98,008	-251,256	-113,552	78,447	316,854	621,104	272,133	167,421	113,083	126,726	450,147	575,330	630,767	576,390
Revenue (ttm)	US$ in thousands	3,809,836	3,720,411	3,685,651	3,662,251	3,569,427	3,471,828	3,371,195	3,194,350	2,999,693	2,864,101	2,628,980	2,436,329	2,361,556	2,277,779	2,214,357	2,184,676	2,158,500	2,053,217	1,985,763	1,953,884
Pretax margin		7.74%	-2.87%	-7.30%	-9.03%	-10.72%	-2.59%	-2.91%	-7.87%	-3.79%	2.74%	12.05%	25.49%	11.52%	7.35%	5.11%	5.80%	20.85%	28.02%	31.76%	29.50%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $294,908K ÷ $3,809,836K
= 7.74%

Jazz Pharmaceuticals plc's pretax margin has shown fluctuations over the quarters analyzed. In Q4 2023, the pretax margin stood at 7.69%, marking an improvement compared to the negative margins observed in the three preceding quarters. This positive trend suggests better cost management or increased revenue generation during the period. However, it is essential to note that the pretax margin was still lower than levels recorded in the same period of the previous year, specifically in Q4 2022. Overall, the company may need to continue monitoring and optimizing its operational efficiency to sustain profitability levels in the future.